---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024720"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:17:11.089712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Windtree reports positive istaroxime interim data in SCAI Stage C cardiogenic shock; plans global Phase 3

## Summary
- Interim analysis of first 20 patients in SEISMiC C Phase 2 study: no new safety signals, hemodynamic improvements consistent with prior trials.
- Istaroxime was added to existing inotropes/vasopressors; no excess arrhythmias observed despite greater illness severity.
- Company cites data as instrumental for moving istaroxime to a global Phase 3 program in heart failure and cardiogenic shock.

## SEC filing metadata
- accession: 0001437749-25-024720
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925024720/0001437749-25-024720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925024720/wint20250805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024720
- JSON: https://secwatch.observer/filing/0001437749-25-024720.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.